Sweaty feet in adolescents-Early use of botulinum type A toxin in juvenile plantar hyperhidrosis.
[BACKGROUND/OBJECTIVES] Plantar hyperhidrosis can have severe social effects on children and adolescents.
APA
Bernhard MK, Krause M, Syrbe S (2018). Sweaty feet in adolescents-Early use of botulinum type A toxin in juvenile plantar hyperhidrosis.. Pediatric dermatology, 35(6), 784-786. https://doi.org/10.1111/pde.13628
MLA
Bernhard MK, et al.. "Sweaty feet in adolescents-Early use of botulinum type A toxin in juvenile plantar hyperhidrosis.." Pediatric dermatology, vol. 35, no. 6, 2018, pp. 784-786.
PMID
30178509
Abstract
[BACKGROUND/OBJECTIVES] Plantar hyperhidrosis can have severe social effects on children and adolescents. Therapeutic options include antiperspirants and surgical interventions (eg, sympathectomy). Botulinum type A toxin is approved for axillary hyperhidrosis in adults only. The aim of the study was the determination of effect and safety of botulinum type A toxin in plantar hyperhidrosis in juvenile patients.
[METHODS] Children and adolescents with idiopathic focal plantar hyperhidrosis were treated with 50-100 U of botulinum type A toxin per sole. Local anesthesia was provided using topical eutectic mixture of local anesthetics cream and ice, in combination with midazolam as an anxiolytic.
[RESULTS] Fifteen patients (aged 12-17) were included in the study. Best results were achieved with a dose of 75-100 U of botulinum type A toxin per sole. Two patients did not benefit from the therapy, and 11 (73%) were satisfied with the results. Nine patients (60%) experienced pain at the injection site for a maximum duration of 3 days. One patient reported transient focal weakness for 4 weeks.
[CONCLUSION] Botulinum type A toxin seems to be a safe secondary treatment option for plantar hyperhidrosis in adolescents aged 12 and older. A dose of 75-100 U per sole resulted in a good therapeutic effect of variable duration in most patients. There were no severe side effects.
[METHODS] Children and adolescents with idiopathic focal plantar hyperhidrosis were treated with 50-100 U of botulinum type A toxin per sole. Local anesthesia was provided using topical eutectic mixture of local anesthetics cream and ice, in combination with midazolam as an anxiolytic.
[RESULTS] Fifteen patients (aged 12-17) were included in the study. Best results were achieved with a dose of 75-100 U of botulinum type A toxin per sole. Two patients did not benefit from the therapy, and 11 (73%) were satisfied with the results. Nine patients (60%) experienced pain at the injection site for a maximum duration of 3 days. One patient reported transient focal weakness for 4 weeks.
[CONCLUSION] Botulinum type A toxin seems to be a safe secondary treatment option for plantar hyperhidrosis in adolescents aged 12 and older. A dose of 75-100 U per sole resulted in a good therapeutic effect of variable duration in most patients. There were no severe side effects.
MeSH Terms
Adolescent; Anesthetics, Local; Botulinum Toxins, Type A; Child; Female; Foot; Humans; Hyperhidrosis; Injections, Intradermal; Male; Sweat; Treatment Outcome